Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Biologic-Naive Patients with Active Psoriatic Arthritis
2011-002326-49Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in psoriatic arthritis (PsA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: American College of Rheumatology 20 Index (ACR20). Started Sep 2012; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2011-002326-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002326-49.